-Quinazolinone CAS 179688-29-0 Erlotinib Hydrochloridis Intermedia Puritas >99.0% (HPLC)
Ducens fabrica et supplementum de Hydrochloride Erlotinib intermedia
Erlotinib Hydrochloridis CAS 183319-69-9
3-Ethynylaniline CAS 54060-30-9
6,7-Bis(2-Methoxyethoxydorum) -3H-Quinazolin-4-unum CAS 179688-29-0
Please contact: alvin@ruifuchem.com
| Nomen chemicum | 6,7-Bis(2-Methoxyethoxy)-3H-Quinazolin-4-unum |
| Synonyma | 6,7-Bis(2-Methoxyethoxy)-4(3H)-Quinazolinone;6,7-Bis(2-Methoxyethoxy)-3,4-Dihydroquinazolin-4-unum;-4-Hydroxyquinazoline;6,7-Bis(2-Methoxyethoxy)-4-Quinazolinol;CP-380736 |
| immunditia | Erlotinib Impuritas A;Erlotinib Lactam Impurity |
| CAS Number | 179688-29-0 |
| CATTUS Number | RF2685 |
| Stock Status | In Stock, Productio Ascendite ad Tons |
| Formulae hypotheticae | C14H18N2O5 |
| M. Pondus | 294.31 |
| Liquescens punctum | 190.0 ad 194.0℃ |
| Density | 1.26±0.1 g/cm3 |
| Sensitiva | Aer Sensitiva |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Aspectus | Alba vel Off-White pulveris |
| Puritas / Analysis Methodus | >99.0% (HPLC) |
| Liquescens punctum | 190.0 ad 194.0℃ |
| Damnum in Siccatio | <0.50% |
| Residere in Ignition | <0.20% |
| Related immunditias ab HPLC | |
| Individual Impurity | <0.50% |
| Totalis immunditias | <1.00% |
| Metalla gravis | <10ppm |
| Infrared Imaginis | Conformat ut Structure |
| Test Standard | Enterprise Standard |
| Consuetudinem | Medium Hydrochloridis Erlotinib (CAS: 183319-69-9) |
sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris
Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore
Quam mercari?Please contact: sales@ruifuchem.com or alvin@ruifuchem.com
15 Years Experience?Plus quam XV annos experientiae habemus in fabricando et exportando amplis intermediis pharmaceuticis vel alchimicis pharmaceuticis amplis.
Mercatus principalis?Vendere mercatum domesticum, Americam septentrionalem, Europam, Indiam, Russiam, Coream, Iaponicam, Australiam etc.
Commodi?Superior qualitas, parabilis pretium, officia professionalia et subsidia technica, ieiunium partus.
Qualitasfides?Qualitas strictioris temperantiae ratio.Pro instrumento analysi professionali includuntur NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, KF, ROI, LOD, MP, Claritas, Solubilitas, Microbialis limes test, etc.
Exempla?Pleraque producta praebent exempla gratuita pro qualitate aestimationis, sumptus naviculas a clientibus solvendos.
Factory Audit?Factory audit gratissimum.Quaeso ante constitutum.
MOQ?Nec MOQ.Parvus ordo placet.
Tempus adferendi? Si intus prosapia, tres dies partus praestatur.
Transportatio?Per Express (FedEx, DHL), ab Air, per Mare.
Documenta?Post servitium venditionis: COA, MOA, ROS, MSDS, etc. praeberi possunt.
Consuetudo Synthesis?Consuetudo synthesis officia praebere potest ad optimas investigationes tuas necessitates aptandas.
Pensio conditio?Proforma cautionis primum post confirmationem ordinis mittetur, informationes nostrae ripae inclusas.Payment by T/T (Telex Transfer), PayPal, Western Union, etc.
6,7-Bis(2-Methoxyethoxydatum)-3H-Quinazolin-4-unum (CAS: 179688-29-0) medium est Hydrochloridis Erlotinib (CAS: 183319-69-9).Hydrochloratum erlotinib est parvum inhibitoris kinasi moleculae tyrosinae, quae convertitur in factorem receptorum epidermalium, hydrochloridum de erlotinib, medicamentum hypotheticum-iaculatum.US cibum et medicamentum Administrationis (FDA) approbavit erlotinib (Tarceva) cum gemcitabine coniunctum sicut curationem primi rectam ad cancer localiter progressus et metastaticus pancreaticus.Praecipue adhibetur ut curatio secunda vel tertia linea pro progresso vel metstatico non-miniculo cancer pulmonis cellulae (NSCLC) et sicut curatio cancer pancreatici.Adhibetur ut inhibitor tyrosinus pro NSCLC curationis.Erlotinib Hydrochlorata parva compositio hypothetica est kinasus receptor inhibitor tyrosinus, qui vetat multiplicationem cellularum tumoris inhibendo phosphorylationem, ligans ad catalyticum intracellularem domain tyrosini kinasi certatum cum ATP, ita amni claudens transductionem insignem et actionem ligandi ligandi tumoris dependens. HER-I/EGFR.
